🔗 Share this article

While the US proceeds with historic changes to its vaccine guidelines, one figure has emerged in a surprising turn: Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by questioning COVID-19 vaccinations during the global health crisis and has concentrated on potential fatalities after Covid vaccination in her recent time at the Food and Drug Administration.

Scheduled Changes to Pediatric Vaccine Schedule

Health officials planned to unveil radical revisions to the childhood immunization program earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US out of alignment with many the global community with little proof for benefit. The announcement has been pushed back until the new year.

Instead of Vinay Prasad, Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the office this year.

Consolidating Power at the FDA

This interim role could signify a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain childhood shot schedules in the US in order to be more in line with Denmark's approach, a nation with universal health coverage and a citizenry approximately the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccination policy – usually the responsibility of Prasad, chief of the FDA’s CBER – instead of drug regulation.

Questions Over Qualifications

Høeg has no obvious background in pharmaceutical research, regulation or leadership, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for running the CDER, stated Jonathan Howard. “She has not conducted a scientific study. She is not versed in leading a large organization. She lacks background in industry regulation.”

Previous directors of CBER would “grasp regulatory frameworks and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who ran the center have had.”

This division has an vast workload at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office approves numerous generic medications. There’s a biosimilars division, non-prescription drug unit and more, and all of those have to be supervised,” Woodcock said. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a major leadership aspect to the job, which manages over 5,000 staff members. “It is a huge administrative position, if you execute it properly,” the former official added.

Agency Reaction and Disputed Policies

In response to concerns about Høeg’s fitness for the role and whether this assignment indicates greater collaboration among FDA leaders on vaccines, a spokesperson said that the “inquiries stem from incorrect presumptions”.

“Her experience aligns with the responsibilities of her position,” the official stated, pointing to the time Dr. Høeg spent advising the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a contentious one-day therapy clearance system that reportedly worried her preceding directors. “By what process are these therapies being selected for this expedited pathway? Who is making the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he said, “the FDA seems to be moving towards laxer oversight of pharmaceuticals, except for immunizations.”

Documented Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if concerning, history, some experts have noted. She authored a study using unverified volunteer-provided data to assess the rate of myocarditis following Covid immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the incoming federal leadership featured changing regulations for new vaccines and discontinuing “optional” immunizations, she said after the election on a podcast. At the agency, Dr. Høeg has according to sources proposed barring teenage boys from getting Covid vaccinations.

“She is an thorough true believer who starts off with her beliefs and tailors the evidence to fit the data in a very disingenuous, untruthful way,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|